Body Text
Competitive advantage
- Multidisciplinary expertise and cross-faculty collaborations
- Developing advanced machine-learning methods and deep-learning models that leverage large omics data
Impact
- Improving translational genomics and personalised medicine
- Facilitating tailored treatment and precision therapy
- Reducing the cost and timeframe of drug development
- Reducing the risk of type 2 diabetes
- Developing downloadable/online toolkits reusable in different clinical settings
Successful outcomes
- Discovery of circulating microRNA markers of colorectal cancer prognosis
- Identification of diagnostic non-coding RNAs in ovarian tumour microenvironment associated with metastasis
- Identification of exosomal microRNA biomarkers for non-invasive glioblastoma diagnosis
- ExomiR signatures of disease status in multiple sclerosis
- Network-based drug repositioning led to identification of less-toxic cancer treatment drugs
- Prediction of functional noncoding variants in human brain genome (in progress)
- Comprehensive databases on mammalian cellular interactions
- Development of computational tools and software for biomarker discovery and drug repurposing
Capabilities and facilities
- High-Performance Computing (HPC) resources for model development
- Access to Australia’s largest genomics facilities with state-of-the-art next-generation sequencing technologies
- Highly multidisciplinary research network enabling translation of the research outcomes
Our partners
- Nutromics Pty Ltd
- BCAL Diagnostics
- Royal Prince Alfred Hospital